ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Timothy Anthony Yap, Howard A. Burris, Shivaani Kummar, Gerald Steven Falchook, Russell Kent Pachynski, Patricia LoRusso, Scott S. Tykodi, Geoffrey Thomas Gibney, Justin F. Gainor, Osama E. Rahma, Tanguy Y. Seiwert, Funda Meric-Bernstam, Mariela A. Blum Murphy, Jennifer Keating Litton, Ellen Michelle Diament Hooper, Heather Anne Hirsch, Christopher Harvey, Myles Clancy, Ty McClure, Margaret K. Callahan
Institutions: The University of Texas MD Anderson Cancer Center, Sarah Cannon, National Cancer Institute, Washington University in St. Louis, Yale Cancer Center, Yale University, University of Washington, Fred Hutch Cancer Center, Moffitt Cancer Center, Massachusetts General Hospital, University of Virginia, University of Chicago, University of Chicago Medical Center, Jounce Therapeutics (United States), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891422389